Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to -$1.9 million.

  • Bolt Biotherapeutics' Change in Accured Expenses fell 52387.39% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.9 million, marking a year-over-year decrease of 69548.65%. This contributed to the annual value of -$4.9 million for FY2024, which is 4307.06% down from last year.
  • Bolt Biotherapeutics' Change in Accured Expenses amounted to -$1.9 million in Q3 2025, which was down 52387.39% from -$840000.0 recorded in Q2 2025.
  • In the past 5 years, Bolt Biotherapeutics' Change in Accured Expenses ranged from a high of $5.6 million in Q3 2022 and a low of -$6.6 million during Q1 2023
  • Moreover, its 5-year median value for Change in Accured Expenses was -$88000.0 (2021), whereas its average is -$215000.0.
  • As far as peak fluctuations go, Bolt Biotherapeutics' Change in Accured Expenses surged by 401568.63% in 2021, and later crashed by 261818.18% in 2022.
  • Over the past 5 years, Bolt Biotherapeutics' Change in Accured Expenses (Quarter) stood at -$549000.0 in 2021, then soared by 152.28% to $287000.0 in 2022, then surged by 313.94% to $1.2 million in 2023, then crashed by 327.1% to -$2.7 million in 2024, then surged by 30.24% to -$1.9 million in 2025.
  • Its Change in Accured Expenses stands at -$1.9 million for Q3 2025, versus -$840000.0 for Q2 2025 and -$2.5 million for Q1 2025.